ArticleFrontiers in cardiovascular medicine2026
Efficacy of SGLT2 inhibitors in patients recently hospitalized for heart failure: an exploratory prespecified pooled analysis of the DELIVER and EMPEROR-preserved trials.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hospitalization for heart failure identifies patients with preserved ejection fraction (HFpEF) at highest risk. However, precise efficacy estimates for sodium-glucose cotransporter 2 (SGLT2) inhibitors in this vulnerable subgroup-and whether they depend on the definition of "recent" hospitalization-are lacking. Methods: This exploratory, hypothesis-generating analysis was a prespecified pooled analysis of the EMPEROR-Preserved and DELIVER trials in patients with HFpEF (LVEF >40%). High-risk subgroups were defined using data from each trial respectively: HF hospitalization within 30 days ("strict", from DELIVER, Results: Treatment with SGLT2 inhibitors reduced the risk of the primary endpoint by 22% in the strict group (HR: 0.78, 95% CI: 0.60-1.03, with a confidence interval that includes the null) and by 27% in the broad group (HR: 0.73, 95% CI: 0.59-0.90). There was no significant heterogeneity between these estimates ( Conclusion: In patients with HFpEF and a recent HF hospitalization, these exploratory findings suggest that SGLT2 inhibitors may provide cardiovascular benefit. The similar direction of effect across two definitions of "recent" (≤30 days and ≤12 months) generates the hypothesis that this high-risk population could benefit, but conclusions are limited by the exploratory, cross-trial design. Further dedicated studies are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.